pI: 10.2029 |
Length (AA): 224 |
MW (Da): 25005 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
NA% percentile | Procyclic, Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_134284)
Species | Accession | Gene Product |
---|---|---|
Babesia bovis | BBOV_IV004720 | MYND finger domain protein, putative |
Cryptosporidium hominis | Chro.40126 | MYND finger domain protein |
Cryptosporidium parvum | cgd4_1070 | MYND finger domain protein |
Leishmania braziliensis | LbrM.35.3770 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_363700.1 | Domain of unknown function (DUF3846)/TPR repeat, putative |
Leishmania infantum | LinJ.36.3700 | hypothetical protein, conserved |
Leishmania major | LmjF.36.3540 | hypothetical protein, conserved |
Neospora caninum | NCLIV_054900 | zinc finger MYND domain-containing protein, putative |
Plasmodium berghei | PBANKA_0101000 | MYND-type zinc finger protein, putative |
Plasmodium falciparum | PF3D7_0602200 | MYND-type zinc finger protein, putative |
Plasmodium knowlesi | PKNH_1148500 | MYND-type zinc finger protein, putative |
Plasmodium vivax | PVX_113275 | hypothetical protein, conserved |
Plasmodium yoelii | PY01862 | hypothetical protein |
Trypanosoma brucei gambiense | Tbg972.11.11140 | hypothetical protein, conserved |
Trypanosoma brucei | Tb11.v5.0355 | TPR repeat, putative |
Trypanosoma brucei | Tb11.v5.0354 | TPR repeat, putative |
Trypanosoma brucei | Tb927.11.9910 | Domain of unknown function (DUF3846)/TPR repeat, putative |
Trypanosoma congolense | TcIL3000.11.10400 | Domain of unknown function (DUF3846)/TPR repeat, putative |
Trypanosoma cruzi | TcCLB.506337.180 | Domain of unknown function (DUF3846)/TPR repeat, putative |
Toxoplasma gondii | TGME49_310850 | MYND finger domain-containing protein |
Theileria parva | TP01_0277 | MYND finger domain protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb11.01.1670 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb11.01.1670 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb11.01.1670 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb11.01.1670 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_310850 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.